Abstract. The dynamics of serum levels of the angiogenic cytokines was investigated, including basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and apoptosis inducer Fas-Ligand (FasL) under the influence of angiotensin-converting enzyme (ACE) enalapril, and the angiotensin II receptor blocker (ARB) candesartan and their combined use in patients with chronic pulmonary  heart disease(CPHD). The study involved 282 patients with CPHD and chronic heart failure (CHF) NYHA Class II-IV. Clinical efficacy of long-term (over 6 months) combined use of ACE inhibitor enalapril and the angiotensin II receptor blocker candesartan on the background of a basic therapy in patients with decompensated CPHD and CHF NYHA Class III-IV judging by the dynamics of bFGF, VEGF, FasLlevels is more pronounced, than during the same treatment but without the angiotensin II receptor blocker